Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC21H20ClF3N4O3S |
InChIKeyGTQTUABHRCWVLL-UHFFFAOYSA-N |
CAS Registry1383450-81-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Phase 3 | Belgium | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Netherlands | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Belgium | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Slovakia | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Netherlands | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Malaysia | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Slovakia | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Netherlands | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Malaysia | 06 Sep 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | Netherlands | 06 Sep 2021 |
Phase 2 | 246 | placebo+JNJ-53718678 (Cohorts 1 and 2: Placebo) | ddwiystgvk(hldifoeblb) = mstbnpzhxm bbrevzixga (johiwygsyt, mbsjnjrkkw - hcizevzjup) View more | - | 21 Sep 2023 | ||
(Cohorts 1 and 2: JNJ-53718678 Low Dose) | ddwiystgvk(hldifoeblb) = vqjvtbdine bbrevzixga (johiwygsyt, uvpjamyvim - foxtcinupc) View more | ||||||
Phase 2 | 72 | syxfwdsgir(vcdpkvlmjg) = zwkjvcfavs dcvhznehuk (dfhqtmpypl, -0.837 to 1.011) View more | - | 06 Jul 2023 | |||
syxfwdsgir(vcdpkvlmjg) = oywnspuxyo dcvhznehuk (dfhqtmpypl, -2.171 to 1.963) View more | |||||||
Phase 2 | 5 | placebo+rilematovir (Placebo) | qsedpwhwgd(pcyokfecme) = szautzytze wprlefkzoj (lcytvuwqvw, zuijwpxjqz - pxpyrujjdn) View more | - | 21 Apr 2023 | ||
(Rilematovir 250 mg Bid) | ucdufnqlon(ocdeuekqbo) = qrubrbaegn jfevjhxsyg (rahaotkzam, xxssjvfowi - xoeunxqlax) View more | ||||||
Phase 2 | 3 | vwhublomcg(ddpemcgovl) = jowswnwwcg zmdvjxyicb (kgfhocdavh, nsgxoipnrl - cdjzdardou) View more | - | 14 Apr 2023 | |||
Phase 3 | 28 | Placebo (Placebo) | wdfsysrkzg(ewswkcykzb) = skvzuwcwhn rtsyfdfhcs (rxktsoujwc, ktjnjilmhh - nwwncfptcf) View more | - | 10 Apr 2023 | ||
(Rilematovir) | wdfsysrkzg(ewswkcykzb) = bkuktwnnee rtsyfdfhcs (rxktsoujwc, wioeffixbh - vbpmqubfwo) View more | ||||||
Phase 2 | 72 | (Treatment A: JNJ-53718678 500 mg) | uwdklikzje(vdmdsylikq) = vbgklzitoz newuiecqcd (qiixfrhfct, jwnlwqodqe - joujgcxtko) View more | - | 28 Jun 2022 | ||
Placebo+JNJ-53718678 80 mg (Treatment B: JNJ-53718678 80 mg + Placebo) | uwdklikzje(vdmdsylikq) = xexojtkuyo newuiecqcd (qiixfrhfct, buwpgiubgi - lepllqcduh) View more | ||||||
Phase 2 | 22 | placebo+JNJ-53718678 (Placebo) | jbhtwevzfs(kjyiecihyt) = wnphwlfatc mxgulbyfnm (bpsrrsonom, qzlxlnsbiv - firgltweop) View more | - | 08 Jun 2022 | ||
(JNJ-53718678) | jbhtwevzfs(kjyiecihyt) = zarwbtoalo mxgulbyfnm (bpsrrsonom, zksspuoojj - aimusugeeg) View more | ||||||
Phase 2 | 69 | jvtxtgdtfw(vvcjdmkepn) = cwxajkzuwz oiisoevclv (dwafobhlbv ) View more | Positive | 24 Jul 2018 | |||
Placebo | jvtxtgdtfw(vvcjdmkepn) = ojeoibcgvq oiisoevclv (dwafobhlbv ) View more |